St. Jude Medical: Results from quadripolar system study show cost savings St. Jude Medical announced that data presented during Heart Rhythm 2014, the Heart Rhythm Society’s Annual Scientific Sessions, found that the use of quadripolar leads reduced the number of hospitalizations by 53% when compared to the non-quadripolar group. This hospitalization rate reduction translated into a statistically significant 62% reduction in overall costs for both health care systems and patients. The Hospitalization Rates and Associated Cost Analysis of Quadripolar versus Bipolar CRT-D: a comparative analysis of a single-center prospective Italian registry presentation includes data that demonstrated hospitalization rates for the quadripolar group were lower than the non-quadripolar group and patients with the St. Jude Medical Quartet Quadripolar LV lead and had a 98% probability of having lower costs than patients with non-quadripolar leads. The study showed that use of the quadripolar left ventricular lead was associated with significantly reduced hospitalizations specific to the two types of hospitalizations studied: heart failure and LV lead surgical revision.
Leerink medical devices analyst holds an analyst/industry conference call Medical Devices Analyst Antalffy discusses the ultimate market opportunity for leadless pacers and compares Medtronic vs St. Jude Medical on an Analyst/Industry conference call to be held on September 24 at 2 pm.
St. Jude Medical recent weakness a buying opportunity, says Barclays Barclays said St. Jude Medical weakness is a buying opportunity. The analyst said CardioMEMS is underappreciated by the Street and valuation compelling given sequential revenue growth. Shares are Overweight rated.